Current treatment status-Not currently treated - Page 4 of 26 Posts on Medivizor
Navigation Menu

Current treatment status-Not currently treated Posts on Medivizor

What schedule of panobinostat with subcutaneous bortezomib and dexamethasone tablets is effective for patients with relapsed and refractory multiple myeloma?

What schedule of panobinostat with subcutaneous bortezomib and dexamethasone tablets is effective for patients with relapsed and refractory multiple myeloma?

Posted by on Dec 31, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the treatment schedule for panobinostat (Farydak) tablets combines with subcutaneous (injections under the skin) bortezomib (Velcade) and dexamethasone (Ozurdex) tablets in patients with relapsed/refractory (R/R) multiple myeloma (MM). The study found that 20mg of panobinostat should be given twice...

Read More

The effects of tandem autologous-reduced intensity allogeneic stem cell transplantation in patients with high-risk relapsed Hodgkin lymphoma

The effects of tandem autologous-reduced intensity allogeneic stem cell transplantation in patients with high-risk relapsed Hodgkin lymphoma

Posted by on Dec 26, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated outcomes of tandem autologous stem cell transplantation (ASCT) – reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (alloSCT) in patients with high-risk (HR) relapsed Hodgkin lymphoma (HL). The main finding was that this approach was safe and effective in such patients. Some...

Read More

Comparing the outcomes of utidelone plus capecitabine versus capecitabine alone in patients with previously treated resistant metastatic breast cancer

Comparing the outcomes of utidelone plus capecitabine versus capecitabine alone in patients with previously treated resistant metastatic breast cancer

Posted by on Dec 26, 2020 in Breast cancer | 0 comments

In a nutshell The study compared outcomes of utidelone plus capecitabine (Xeloda) versus capecitabine (C) alone in previously treated patients with anthracycline- and taxane-resistant metastatic breast cancer (MBC). The authors found that this combination improved survival compared to C alone in such patients. Some background...

Read More

Searching for participants with advanced non-small cell lung cancer to trial an experimental therapy

Searching for participants with advanced non-small cell lung cancer to trial an experimental therapy

Posted by on Dec 15, 2020 in Lung cancer | 0 comments

In a nutshell This trial is evaluating the safety and effectiveness of experimental treatment REGN5093 in patients with advanced non-small-cell lung cancer (NSCLC). The main outcomes to be evaluated will be the number of patients who experience side effects, the maximum dose without significant side effects, and response to treatment. This trial is...

Read More

Searching for patients with advanced breast cancer to trial an experimental combination treatment.

Searching for patients with advanced breast cancer to trial an experimental combination treatment.

Posted by on Dec 13, 2020 in Breast cancer | 0 comments

In a nutshell This trial is looking to examine the safety and effectiveness of a new drug called CYH33 in combination with olaparib (Lynparza) for the treatment of advanced solid tumors including breast cancer. The main outcomes that are to be measured are side effects and the response rate to the treatment. This trial is being carried out in...

Read More

Evaluating tisagenlecleucel in a real world setting for patients with acute lymphoblastic leukemia and non-Hodgkin lymphoma

Evaluating tisagenlecleucel in a real world setting for patients with acute lymphoblastic leukemia and non-Hodgkin lymphoma

Posted by on Dec 5, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of tisagenlecleucel (TL; Kymriah) in a real-world setting as a treatment for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).   This study concluded that TL has similar effectiveness and improved safety in a real-world setting when compared to a trial...

Read More

Tisagenlecleucel in a real world setting for patients with acute lymphoblastic leukemia and non-Hodgkin lymphoma

Tisagenlecleucel in a real world setting for patients with acute lymphoblastic leukemia and non-Hodgkin lymphoma

Posted by on Dec 5, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of tisagenlecleucel (TL; Kymriah) in a real-world setting as a treatment for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).   This study concluded that TL has similar effectiveness and improved safety in a real-world...

Read More

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Searching for patients with EGFR-positive advanced tumors to trial an experimental treatment.

Posted by on Nov 22, 2020 in Melanoma | 0 comments

In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced...

Read More

Evaluating the impact of novel agents on allogeneic stem cell transplant outcomes for chronic lymphocytic leukemia 

Evaluating the impact of novel agents on allogeneic stem cell transplant outcomes for chronic lymphocytic leukemia 

Posted by on Oct 17, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if allogeneic stem cell transplantation (allo-SCT) was a safe and effective option for the treatment of patients with chronic lymphocytic leukemia (CLL) after treatment with novel agents (NA).  This study concluded that this treatment option was safe and effective for patients with...

Read More

Cladribine, G-CSF, cytarabine and aclarubicin in patients with relapsed/refractory acute myeloid leukemia 

Cladribine, G-CSF, cytarabine and aclarubicin in patients with relapsed/refractory acute myeloid leukemia 

Posted by on Oct 17, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of C-CAG including cladribine (Leustatin), granulocyte colony-stimulating factor (G-CSF, Neupogen), cytarabine (Cytosar-U), and aclarubicin (Aclacinon) in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML).   This study...

Read More